Effects of Bortezomib and Dexamethasone combination on treating senile multiple myeloma and influence on immune suppressed factors and immune cell levels

Objective:To investigate the effects of Bortezomib and Dexamethasone combination on treating senile multiple myeloma and influence on immune suppressed factors and immune cell levels.Methods:A total of 80 cases of patients with multiple myeloma treated in our hospital from Oct 2013 to Jul 2015 were selected as investigate subjects. They were randomly divided to be observation group consisted of 43 cases and control group consisted of 37 cases. For observation group, treatment of Bortezomib and Dexamethasone combination was provided. For control group, Vincristine + Epirubicin + Dexamethasone treatment was provided. After three courses, effects on two groups of patients were compared, and immune suppressed factors and immune cell levels before and after treatment in different periods were compared.Results:After three courses of treatment, the total effective rate in observation group was significantly higher than control group. Before treatment, IL-6, IL-17, TGF-β, CD3+CD4+, CD3+CD8+ and CD3+CD4+/CD3+CD8+ between the two group of patients were compared, no significant difference showed;After treatment for 6 weeks, IL-6, IL-17 levels in observation group were significantly decreased comparing with the same group before treatment;After treatment for 12 weeks, IL-6, IL-17 and TGF-β levels in observation group were significantly decreased comparing with the same group before treatment;After treatment, IL-6, IL-17 levels in observation group were significantly lower than control group at the same phase. After treatment for 12 weeks, CD3+CD4+, CD3+CD4+/CD3+CD8+ in observation group were significantly higher than the same group before treatment, and significantly higher than control group at the same phase;CD3+CD8+ in observation group was significantly lower than the same group before treatment, and significantly lower than control group at the same phase. Conclusion:Compared with Vincristine + Epirubicin + Dexamethasone treatment, Bortezomib and Dexamethasone combination on treating senile multiple myeloma had more significant effects, which deserves further clinical researches.